Insider Transactions in Q1 2024 at Ionis Pharmaceuticals Inc (IONS)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Feb 29
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Other acquisition or disposition
|
Direct |
383
+0.48%
|
$13,022
$34.42 P/Share
|
|
Feb 29
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Other acquisition or disposition
|
Direct |
604
+1.32%
|
$20,536
$34.42 P/Share
|
|
Feb 29
2024
|
Richard S Geary EVP, Chief Development Officer |
BUY
Other acquisition or disposition
|
Direct |
604
+0.68%
|
$20,536
$34.42 P/Share
|
|
Feb 29
2024
|
Brett P Monia Chief Executive Officer |
BUY
Other acquisition or disposition
|
Direct |
538
+0.31%
|
$18,292
$34.42 P/Share
|
|
Feb 29
2024
|
Eric Swayze EVP Research |
BUY
Other acquisition or disposition
|
Direct |
605
+1.7%
|
$20,570
$34.42 P/Share
|
|
Feb 16
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
387
-0.22%
|
$17,028
$44.49 P/Share
|
|
Feb 02
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
1,853
-2.29%
|
$90,797
$49.52 P/Share
|
|
Feb 02
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Open market or private sale
|
Direct |
2,125
-5.6%
|
$104,125
$49.6 P/Share
|
|
Feb 02
2024
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
1,961
-2.2%
|
$98,050
$50.04 P/Share
|
|
Feb 02
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
2,125
-2.24%
|
$104,125
$49.54 P/Share
|
|
Feb 02
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
23,501
-11.89%
|
$1,151,549
$49.37 P/Share
|
|
Feb 02
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
1,961
-3.87%
|
$96,089
$49.67 P/Share
|
|
Feb 02
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
2,071
-3.99%
|
$101,479
$49.59 P/Share
|
|
Feb 02
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
1,907
-5.26%
|
$93,443
$49.56 P/Share
|
|
Feb 01
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,609
+4.27%
|
-
|
|
Feb 01
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Grant, award, or other acquisition
|
Direct |
4,140
+9.84%
|
-
|
|
Feb 01
2024
|
Richard S Geary EVP, Chief Development Officer |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+4.1%
|
-
|
|
Feb 01
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Grant, award, or other acquisition
|
Direct |
4,140
+4.17%
|
-
|
|
Feb 01
2024
|
Brett P Monia Chief Executive Officer |
BUY
Grant, award, or other acquisition
|
Direct |
45,788
+10.94%
|
-
|
|
Feb 01
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Grant, award, or other acquisition
|
Direct |
3,820
+7.02%
|
-
|
|
Feb 01
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Grant, award, or other acquisition
|
Direct |
4,033
+7.21%
|
-
|
|
Feb 01
2024
|
Eric Swayze EVP Research |
BUY
Grant, award, or other acquisition
|
Direct |
3,715
+9.3%
|
-
|
|
Jan 31
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
10,773
-24.89%
|
$560,196
$52.0 P/Share
|
|
Jan 25
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
6,450
-12.11%
|
$328,950
$51.75 P/Share
|
|
Jan 25
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
2,285
-1.48%
|
$116,535
$51.75 P/Share
|
|
Jan 17
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
SELL
Open market or private sale
|
Direct |
5,564
-14.13%
|
$278,200
$50.42 P/Share
|
|
Jan 17
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
SELL
Open market or private sale
|
Direct |
7,744
-12.7%
|
$387,200
$50.42 P/Share
|
|
Jan 17
2024
|
Brian Birchler EVP, Corp and Development Ops |
SELL
Open market or private sale
|
Direct |
4,497
-9.16%
|
$224,850
$50.42 P/Share
|
|
Jan 17
2024
|
Richard S Geary EVP, Chief Development Officer |
SELL
Open market or private sale
|
Direct |
7,338
-7.91%
|
$366,900
$50.42 P/Share
|
|
Jan 17
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
SELL
Open market or private sale
|
Direct |
8,683
-8.72%
|
$434,150
$50.42 P/Share
|
|
Jan 17
2024
|
Brett P Monia Chief Executive Officer |
SELL
Open market or private sale
|
Direct |
32,059
-17.22%
|
$1,602,950
$50.42 P/Share
|
|
Jan 17
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
5,482
-10.28%
|
$274,100
$50.42 P/Share
|
|
Jan 17
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Indirect |
9
-9.57%
|
$450
$50.42 P/Share
|
|
Jan 17
2024
|
Eric Swayze EVP Research |
SELL
Open market or private sale
|
Direct |
6,296
-12.7%
|
$314,800
$50.42 P/Share
|
|
Jan 17
2024
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Indirect |
564
-25.59%
|
$28,200
$50.42 P/Share
|
|
Jan 17
2024
|
Joseph Baroldi EVP, Chief Business Officer |
SELL
Open market or private sale
|
Direct |
1,460
-10.24%
|
$73,000
$50.42 P/Share
|
|
Jan 17
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
SELL
Open market or private sale
|
Direct |
6,745
-8.02%
|
$337,250
$50.42 P/Share
|
|
Jan 16
2024
|
Onaiza Cadoret Manier EVP, Chf GL Pdt Str & Oper Ofc |
BUY
Exercise of conversion of derivative security
|
Direct |
15,062
+27.67%
|
-
|
|
Jan 16
2024
|
Patrick R. O'Neil EVP CLO & General Counsel |
BUY
Exercise of conversion of derivative security
|
Direct |
20,641
+25.28%
|
-
|
|
Jan 16
2024
|
Brian Birchler EVP, Corp and Development Ops |
BUY
Exercise of conversion of derivative security
|
Direct |
12,080
+19.75%
|
-
|
|
Jan 16
2024
|
Richard S Geary EVP, Chief Development Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
19,852
+17.62%
|
-
|
|
Jan 16
2024
|
Elizabeth L Hougen EVP, Finance & CFO |
BUY
Exercise of conversion of derivative security
|
Direct |
22,487
+18.42%
|
-
|
|
Jan 16
2024
|
Brett P Monia Chief Executive Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
68,084
+26.78%
|
-
|
|
Jan 16
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
BUY
Exercise of conversion of derivative security
|
Direct |
15,162
+22.14%
|
-
|
|
Jan 16
2024
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Indirect |
21
+18.26%
|
-
|
|
Jan 16
2024
|
Eric Swayze EVP Research |
BUY
Exercise of conversion of derivative security
|
Direct |
17,069
+25.61%
|
-
|
|
Jan 16
2024
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Indirect |
1,353
+38.04%
|
-
|
|
Jan 16
2024
|
Joseph Baroldi EVP, Chief Business Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
3,688
+20.55%
|
-
|
|
Jan 16
2024
|
C Frank Bennett EVP, Chief Scientific Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
18,314
+17.89%
|
-
|
|
Jan 12
2024
|
Eugene Schneider EVP, Chf Clinical Develop Ofcr |
SELL
Open market or private sale
|
Direct |
8,000
-17.33%
|
$424,000
$53.5 P/Share
|